{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:07:48Z","timestamp":1790539668094,"version":"4.1.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:p>Background: Amyloid-\u03b242 (A\u03b242) is associated with plaque formation in the brain of patients with Alzheimer\u2019s disease (AD). Studies have suggested the potential utility of plasma A\u03b242 levels in the diagnosis, and in longitudinal study of AD pathology. Conventional ELISAs are used to measure A\u03b242 levels in plasma but are not sensitive enough to quantitate low levels. Although ultrasensitive assays like single molecule array or immunoprecipitation-mass spectrometry have been developed to quantitate plasma A\u03b242 levels, the high cost of instruments and reagents limit their use. Objective: We hypothesized that a sensitive and cost-effective chemiluminescence (CL) immunoassay could be developed to detect low A\u03b242 levels in human plasma. Methods: We developed a sandwich ELISA using high affinity rabbit monoclonal antibody specific to A\u03b242. The sensitivity of the assay was increased using CL substrate to quantitate low levels of A\u03b242 in plasma. We examined the levels in plasma from 13 AD, 25 Down syndrome (DS), and 50 elderly controls. Results: The measurement range of the assay was 0.25 to 500\u200apg\/ml. The limit of detection was 1\u200apg\/ml. All AD, DS, and 45 of 50 control plasma showed measurable A\u03b242 levels. Conclusion: This assay detects low levels of A\u03b242 in plasma and does not need any expensive equipment or reagents. It offers a preferred alternative to ultrasensitive assays. Since the antibodies, peptide, and substrate are commercially available, the assay is well suited for academic or diagnostic laboratories, and has a potential for the diagnosis of AD or in clinical trials.<\/jats:p>","DOI":"10.3233\/jad-200861","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T12:34:29Z","timestamp":1604061269000},"page":"1237-1244","source":"Crossref","is-referenced-by-count":21,"title":["A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-\u03b2 1-42 Peptide in Human Plasma"],"prefix":"10.1177","volume":"78","author":[{"given":"Pankaj D.","family":"Mehta","sequence":"first","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Patrick","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Miller","sequence":"additional","affiliation":[{"name":"New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Coyle","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stony Brook University, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Center for Cognitive Neurology, New York University School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200861_ref1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"Contributors NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Alzheimer disease","volume":"167","author":"Soria Lopez","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.3233\/JAD-200861_ref3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer\u2019s fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200861_ref5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/jcm9061673","article-title":"Diagnostic biomarkers for Alzheimer\u2019s disease using noninvasive specimens","volume":"9","author":"Paraskevaidi","year":"2020","journal-title":"J Clin Med"},{"key":"10.3233\/JAD-200861_ref6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic","volume":"11","author":"Hampel","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-200861_ref7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer disease: Current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J Int Med"},{"key":"10.3233\/JAD-200861_ref8","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s40120-017-0073-9","article-title":"A review of fluid biomarkers for Alzheimer disease: Moving from CSF to blood","volume":"6","author":"Blennow","year":"2017","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-200861_ref9","first-page":"e12020","article-title":"Amyloid accumulation in Down syndrome measured with amyloid load","volume":"12","author":"Zammit","year":"2020","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-200861_ref10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0b013e3181fb448b","article-title":"Change in plasma A\u03b2 peptides and onset of dementia in adults with Down syndrome","volume":"75","author":"Schupf","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-200861_ref11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-200861_ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0444-1","article-title":"Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: The Fundacio ACE Healthy Brain Initiative (FACEHBI)","volume":"10","author":"de Rojas","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200861_ref13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JAD-190533","article-title":"Ultrasensitive detection of plasma amyloid-beta as a biomarker for cognitively normal elderly individuals at risk of Alzheimer\u2019s disease","volume":"71","author":"Chatterjee","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","article-title":"Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals","volume":"8","author":"Fandos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-200861_ref15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid beta 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-180321","article-title":"Plasma A\u03b242 as biomarker of prodromal Alzheimer disease progression in patients with amnestic mild cognitive impairment: Evidence from the phrmacog\/E \u2013ADNI study","volume":"69","author":"Albani","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-200861_ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/JAD-143189","article-title":"Characterizing aging, mild cognitive impairment, and dementia with blood-based biomarkers and neuropsychology","volume":"50","author":"Kleinschmidt","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref19","doi-asserted-by":"crossref","first-page":"14052","DOI":"10.1073\/pnas.0805902105","article-title":"Peripheral A\u03b2 subspecies as risk biomarkers of Alzheimer\u2019s disease","volume":"105","author":"Schupf","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200861_ref20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200861_ref21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-180140","article-title":"Elevation of plasma amyloid-beta level is more significant in early stage of cognitive impairment: A population-based cross-sectional study","volume":"64","author":"Wang","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-018-0395-6","article-title":"Plasma amyloid \u03b2 levels, cerebral atrophy, and risk of dementia: A population based study","volume":"10","author":"Hillal","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200861_ref23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jalz.2014.07.001","article-title":"Plasma amyloid-beta and risk of Alzheimer\u2019s disease in the Framingham Heart Study","volume":"11","author":"Chouraki","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jalz.2012.12.006","article-title":"Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer\u2019s disease","volume":"10","author":"Rembach","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200861_ref26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2010.1995","article-title":"Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline","volume":"305","author":"Yaffe","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-200861_ref27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-2011-111418","article-title":"Evaluation of plasma A\u03b2 as predictor of Alzheimer\u2019s disease in older individuals without dementia: A population- based study","volume":"28","author":"Hansson","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref28","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-200861_ref29","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200861_ref30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200861_ref31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-016-0225-7","article-title":"A digital ELISA for ultrasensitive measurement of amyloid \u03b2 1-42 peptide in human plasma with utility for studies of Alzheimer\u2019s disease therapeutics","volume":"8","author":"Song","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200861_ref32","first-page":"13894","article-title":"Plasma A\u03b242 and total tau predict cognitive decline in amnestic mild cognitive impairment","volume":"9","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.3233\/JAD-200861_ref33","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s40120-017-0074-8","article-title":"Amyloid \u03b2 and tau as Alzheimer disease blood biomarkers: Promise from new technologies","volume":"6","author":"Lue","year":"2017","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-200861_ref34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2010-101341","article-title":"High-affinity rabbit monoclonal antibodies specific for amyloid peptides A\u03b240 and A\u03b242","volume":"23","author":"Miller","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13506120601116500","article-title":"Humoral immune response to peptides derived from the beta-amyloid peptide C-terminal sequence","volume":"14","author":"Miller","year":"2007","journal-title":"Amyloid"},{"key":"10.3233\/JAD-200861_ref36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantitation of the neurofilament light chain in blood samples: Elisa, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.3233\/JAD-200861_ref37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3233\/JAD-142592","article-title":"Generation of rabbit monoclonal antibody to amyloid-\u03b238: Increased plasma A\u03b238 levels in Down syndrome","volume":"46","author":"Mehta","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3233\/JAD-190714","article-title":"Amyloid \u03b2 as a blood biomarker for Alzheimer disease: A review of recent literature","volume":"73","author":"Wang","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3233\/JAD-143099","article-title":"Diagnostic values of CSF fluid t-tau and A\u03b242 using meso scale discovery assays for Alzheimer disease","volume":"45","author":"Pan","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JAD-2010-100456","article-title":"Comparison of conventional ELISA with technology for detection of amyloid-\u03b2 in plasma","volume":"21","author":"Oh","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200861_ref41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:20Z","timestamp":1777370660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":41,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-200861","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]}}}